<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>370</serviceExecutionTime><Drug id="53085"><DrugName>REC-2282</DrugName><DrugSynonyms><Name><Value>HDAC-42</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>histone deacetylase inhibitors, Ohio State University</Value></Name><Name><Value>VAD-20</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VAD-18</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>OSU-HDAC-42</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>s-HDAC-42</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NSC-736012</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>NSC-731438</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AR-42 (cancer), Arno Therapeutics</Value></Name><Name><Value>NSC-D736012</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AR-42</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>pan-histone deacetylase inhibitor (neurofibromatosis type 2), Recursion</Value></Name><Name><Value>REC-2282</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20649">Ohio State University</CompanyOriginator><CompaniesPrimary><Company id="1096979">Recursion Pharmaceuticals LLC</Company></CompaniesPrimary><CompaniesSecondary><Company id="1037343">Arno Therapeutics Inc</Company><Company id="20649">Ohio State University</Company></CompaniesSecondary><CrossReferences><SourceEntity id="53085" type="Drug"><TargetEntity id="403161" type="siDrug">AR-42</TargetEntity></SourceEntity><SourceEntity id="1037343" type="Company"><TargetEntity id="4296077599" type="organizationId">Arno Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="1096979" type="Company"><TargetEntity id="5042238812" type="organizationId">Recursion Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="20649" type="Company"><TargetEntity id="5000861728" type="organizationId">Ohio State University</TargetEntity></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"></TargetEntity><TargetEntity id="10028228" type="MEDDRA"></TargetEntity><TargetEntity id="D009101" type="MeSH"></TargetEntity><TargetEntity id="29073" type="ORPHANET"></TargetEntity><TargetEntity id="-18870694" type="omicsDisease"></TargetEntity><TargetEntity id="710" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"></TargetEntity><TargetEntity id="D019337" type="MeSH"></TargetEntity><TargetEntity id="-105358819" type="omicsDisease"></TargetEntity><TargetEntity id="1328" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2464" type="ciIndication"><TargetEntity id="10000523" type="MEDDRA"></TargetEntity><TargetEntity id="D009464" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="2802" type="ciIndication"><TargetEntity id="10027191" type="MEDDRA"></TargetEntity><TargetEntity id="D008579" type="MeSH"></TargetEntity><TargetEntity id="2495" type="ORPHANET"></TargetEntity><TargetEntity id="-54797992" type="omicsDisease"></TargetEntity><TargetEntity id="1466" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3522" type="ciIndication"><TargetEntity id="Q85.02" type="ICD10"></TargetEntity><TargetEntity id="D016518" type="MeSH"></TargetEntity><TargetEntity id="637" type="ORPHANET"></TargetEntity><TargetEntity id="-108005238" type="omicsDisease"></TargetEntity><TargetEntity id="2310" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="2574" type="Action"><TargetEntity id="1213" type="Mechanism">Histone Deacetylase (HDAC) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3522">Neurofibromatosis type II</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1828">Multiple myeloma</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="2464">Acoustic neuroma</Indication><Indication id="2802">Meningioma</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="2574">Histone deacetylase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-05-30T04:25:32.000Z</LastModificationDate><ChangeDateLast>2019-01-29T00:00:00.000Z</ChangeDateLast><AddedDate>2005-04-25T16:02:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1096979" linkType="Company"&gt;Recursion&lt;/ulink&gt;, under license from &lt;ulink linkID="1093776" linkType="Company"&gt;Ohio State Innovation Foundation&lt;/ulink&gt; (OSIF), the technology transfer function of  &lt;ulink linkID="20649" linkType="Company"&gt;Ohio State University&lt;/ulink&gt; (OSU), is investigating    REC-2282 (previously known as AR-42; OSU-HDAC-42; NSC-D736012; s-HDAC-42; structure shown) an orally available pan-HDAC  inhibitor,  for the potential treatment of neurofibromatosis type 2 (NF2)  [&lt;ulink linkID="595624" linkType="Reference"&gt;595624&lt;/ulink&gt;], [&lt;ulink linkID="750709" linkType="Reference"&gt;750709&lt;/ulink&gt;], [&lt;ulink linkID="2108363" linkType="Reference"&gt;2108363&lt;/ulink&gt;].  In January 2019, Recursion planned to initiate first-in-human clinical trials in NF2 as soon as possible [&lt;ulink linkID="2108363" linkType="Reference"&gt;2108363&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1037343" linkType="Company"&gt;Arno Therapeutics&lt;/ulink&gt;, under license from OSU, was previously developing the drug (as AR-42) for the potential treatment of cancer, including hematological malignancies and solid tumors  [&lt;ulink linkID="871583" linkType="Reference"&gt;871583&lt;/ulink&gt;],  [&lt;ulink linkID="871772" linkType="Reference"&gt;871772&lt;/ulink&gt;],  [&lt;ulink linkID="1037803" linkType="Reference"&gt;1037803&lt;/ulink&gt;],  [&lt;ulink linkID="1269388" linkType="Reference"&gt;1269388&lt;/ulink&gt;], [&lt;ulink linkID="1467844" linkType="Reference"&gt;1467844&lt;/ulink&gt;]; the company was also investigating REC-2282 for  the potential treatment of central nervous system tumors including NF2, meningioma and schwannoma [&lt;ulink linkID="1265503" linkType="Reference"&gt;1265503&lt;/ulink&gt;], [&lt;ulink linkID="1272842" linkType="Reference"&gt;1272842&lt;/ulink&gt;]. In June 2010, the company began a phase I/II trial in patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL) or lymphoma [&lt;ulink linkID="1108806" linkType="Reference"&gt;1108806&lt;/ulink&gt;], [&lt;ulink linkID="1109679" linkType="Reference"&gt;1109679&lt;/ulink&gt;];  in June 2016, phase I data were presented [&lt;ulink linkID="1767408" linkType="Reference"&gt;1767408&lt;/ulink&gt;].   In October 2015, a phase Ib trial  was planned to begin in the US in patients with   multiple myeloma in June 2016. The trial was to end in March 2019  [&lt;ulink linkID="1760979" linkType="Reference"&gt;1760979&lt;/ulink&gt;]. However, in November 2017, Arno returned the rights to REC-2282 to OSIF [&lt;ulink linkID="2108363" linkType="Reference"&gt;2108363&lt;/ulink&gt;]; and in December 2017, the company was   dissolved and   all development by the company was discontinued [&lt;ulink linkID="1993745" linkType="Reference"&gt;1993745&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;OSU was  previously investigating  other HDAC inhibitors under the RAID program at &lt;ulink linkID="20519" linkType="Company"&gt;NCI&lt;/ulink&gt;, including    VAD-18,  VAD-20 (Zn2+-chelating, short chain fatty acids) [&lt;ulink linkID="595624" linkType="Reference"&gt;595624&lt;/ulink&gt;]; however, it is presumed that  REC-2282 was selected as the lead compound of that series.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In February 2012, the FDA granted Orphan Drug status to  REC-2282 for meningioma and schwannoma [&lt;ulink linkID="1265503" linkType="Reference"&gt;1265503&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2012, the EMA recommended granting the drug Orphan designation for the treatment of NF2 [&lt;ulink linkID="1272842" linkType="Reference"&gt;1272842&lt;/ulink&gt;]; in April 2012, the EMA granted Orphan Drug status to  REC-2282 for NF2 [&lt;ulink linkID="1289901" linkType="Reference"&gt;1289901&lt;/ulink&gt;], [&lt;ulink linkID="1293411" linkType="Reference"&gt;1293411&lt;/ulink&gt;]. In April 2012, the drug was recommended for Orphan status for meningioma and schwannoma [&lt;ulink linkID="1282471" linkType="Reference"&gt;1282471&lt;/ulink&gt;]; in  June 2012, the EMA granted Orphan Drug status to  REC-2282 for meningioma and schwannoma [&lt;ulink linkID="1298806" linkType="Reference"&gt;1298806&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In January 2019, Recursion planned to build on existing clinical data to advance REC-2282  to first-in-human clinical trials in NF2 as rapidly as possible [&lt;ulink linkID="2108363" linkType="Reference"&gt;2108363&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In July 2016, an open-label, single group assigned, phase I trial (&lt;ulink linkID="262934" linkType="Protocol"&gt;NCT02795819&lt;/ulink&gt;; MCC-14-10774) began in the US in patients (expected n = 51) with advanced soft tissue sarcoma and renal cell carcinoma to evaluate the safety and efficacy of AR-41 in combination with &lt;ulink linkID="43738" linkType="Drug"&gt;pazopanib&lt;/ulink&gt;. By November 2016, enrollment had been suspended due to protocol revisions. In May 2017, the trial was expected to complete in June 2025 [&lt;ulink linkID="1773587" linkType="Reference"&gt;1773587&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 2012, the company had planned to initiate an investigator-initiated study in collaboration with OSU in patients with meningioma and schwannoma  [&lt;ulink linkID="1467844" linkType="Reference"&gt;1467844&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2009, an IND filing was accepted by the FDA [&lt;ulink linkID="992635" linkType="Reference"&gt;992635&lt;/ulink&gt;]. In June 2010, the company began a phase I/II, open-label, single-agent dose-escalation  trial in 50 patients with MM, CLL or lymphoma and solid tumor [&lt;ulink linkID="1108806" linkType="Reference"&gt;1108806&lt;/ulink&gt;], [&lt;ulink linkID="1109679" linkType="Reference"&gt;1109679&lt;/ulink&gt;], [&lt;ulink linkID="1467844" linkType="Reference"&gt;1467844&lt;/ulink&gt;].  In November 2010, phase I data were presented at CHI's Fourth Annual HDAC inhibitors Conference in Boston, MA. At that time, six patients had been treated in two dose cohorts (20 and 40 mg qd tiw). One grade 3 thrombocytopenia had been observed and a minor response was seen in an MM patient. There was accumulation of drug in plasma at day 19 of treatment [&lt;ulink linkID="1149610" linkType="Reference"&gt;1149610&lt;/ulink&gt;]. In September 2011, phase II part of the study was anticipated to initiate in the second quarter of 2012 [&lt;ulink linkID="1269391" linkType="Reference"&gt;1269391&lt;/ulink&gt;]. In March 2012, the phase I/IIa study was ongoing  [&lt;ulink linkID="1269388" linkType="Reference"&gt;1269388&lt;/ulink&gt;]. In December 2012, data were presented from first-in-human study, at the 54th ASH Annual meeting in Atlanta, GA.    Patients (n = 17) received REC-2282 (20, 40, 50 and 70 mg po tiw). MTD was determined to be 40 mg. REC-2282 was  rapidly absorbed with no accumulation of REC-2282 in the plasma. In MM and mantle cell lymphoma, best responses were observed. At that time, the enrollment in the expansion cohort was ongoing [&lt;ulink linkID="1347980" linkType="Reference"&gt;1347980&lt;/ulink&gt;]. In June 2016, further clinical data from &lt;ulink linkID="66702" linkType="Protocol"&gt;NCT01129193&lt;/ulink&gt; study in 17 patients were presented at the 52nd ASCO meeting in Chicago, IL. . DLTs reported were two grade 3 thrombocytopenia at 60 mg and one grade 4 psychiatric disorder, possibly related to REC-2282 (at 80 mg). Stable disease as the best response was achieved by 53% of patients, with median progression-free survival  of 4.4 months. Across the dose range, Cmax and AUC (0 to 24 h) values were ranged from 0.54 to 3.25 microM and 4.93 to 27.6 microM.h, respectively. Overall, REC-2282 was well-tolerated and MTD was found to be 60 mg, qd, tiw (q2d), 3-week on and 1-week off (28-day cycle) [&lt;ulink linkID="1767408" linkType="Reference"&gt;1767408&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2015, a phase Ib trial (&lt;ulink linkID="242196" linkType="Protocol"&gt;NCT02569320&lt;/ulink&gt;; OSU-15004; NCI-2015-01557; PO-CL-MM-PI-003687) was planned to be begin in the US in patients (n = 72)   with multiple myeloma in June 2016. The trial was to end in March 2019  [&lt;ulink linkID="1760979" linkType="Reference"&gt;1760979&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2015, preclinical data from in vitro and in vivo studies of xenograft model were published. Data demonstrated that, REC-2282   in combination with cisplatin showed a synergistic effect  with the destruction of bladder cancer cells through apoptosis by influencing tumor growth and differentiation. The drug was observed with greater efficacy on CD44+ and CD49f+ bladder cancer stem cell population  in combination with and without cisplatin  [&lt;ulink linkID="1644632" linkType="Reference"&gt;1644632&lt;/ulink&gt;], [&lt;ulink linkID="1644541" linkType="Reference"&gt;1644541&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, preclinical data were presented at the 105th AACR meeting in San Diego, CA. Administration of REC-2282 (50 mg/kg, po, bid) was associated with reduced cachexia-associated weight loss without any significant effect on the tumor burden in C-26 (colon cancer) xenograft mice. In mice bearing C-26 tumors, REC-2282 (50 mg/kg, po, bid) prolonged survival compared with &lt;ulink linkID="17625" linkType="Drug"&gt;vorinostat&lt;/ulink&gt; and &lt;ulink linkID="8023" linkType="Drug"&gt;romidepsin&lt;/ulink&gt;; gene expression patterns and metabolic profiles were maintained by REC-2282 similar to that of non-cachetic muscles [&lt;ulink linkID="1540299" linkType="Reference"&gt;1540299&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2013, preclinical data had demonstrated that REC-2282 showed anti-tumor activity in meningioma and schwannoma tumor types [&lt;ulink linkID="1467844" linkType="Reference"&gt;1467844&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 102nd AACR meeting in Orlando, FL.  REC-2282  induced cell death in leukemia cell lines, including HL-60, U937 and MV 4-11, and in primary   human acute myeloid leukemia (AML) stem cells.  In NOD/SCID mice bearing AML transplants, the leukemia progenitor and stem cell activity was ablated by REC-2282. The anti-leukemia stem cell activity of REC-2282 was mediated through NF-kappaB induction, caspase activation, apoptosis induction and HSP90 inhibition. REC-2282 did not activate HMOX-1 [&lt;ulink linkID="1177376" linkType="Reference"&gt;1177376&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2009, preclinical data were presented at the 100th AACR meeting in Denver, CO. In vitro, REC-2282 induced apoptosis, displayed tumor inhibition with a mean IC50 value of 0.39 microM, dephosphorylated Akt and downregulated Bcl-2, Bcl-xL and survivin. In  mouse xenografts, oral OSU-HDAC-42 at 20 mg/kg per day inhibited cancer cell growth [&lt;ulink linkID="997891" linkType="Reference"&gt;997891&lt;/ulink&gt;]. Further data were presented at the meeting which showed that REC-2282-treatment of malignant mast cell lines induced loss of cell viability, cell cycle arrest, induction of caspase-3,7 activity and apoptosis. Ex vivo, REC-2282 induced the activation of caspase-3,7 in fresh canine malignant mast cells, leading to apoptosis [&lt;ulink linkID="998332" linkType="Reference"&gt;998332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2008, Arno was conducting IND-enabling studies [&lt;ulink linkID="871772" linkType="Reference"&gt;871772&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In April 2008, preclinical data on REC-2282 were presented at the 99th AACR annual meeting in San Diego, CA, showing that the drug was  a potent inhibitor of HDAC and cell survival in canine and human osteosarcoma cells; it also had  a more potent effect than &lt;ulink linkID="17625" linkType="Drug"&gt;vorinostat&lt;/ulink&gt; [&lt;ulink linkID="895090" linkType="Reference"&gt;895090&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2008, REC-2282 was shown to have a greater potency and a competitive profile compared to vorinostat  in solid and liquid tumors [&lt;ulink linkID="871772" linkType="Reference"&gt;871772&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, preclinical data on OSU-HDAC-42 were presented at the 98th AACR meeting in Los Angeles, CA. When tested in Hep3B, Huh7, and PLC5 HCC cell lines, the agent demonstrated superior potency over vorinostat (IC50 = 0.5 microM and 3 to 5 microM, respectively). OSU-HDAC-42 (25 mg/kg/day)  was better at suppressing PLC5 tumor growth and did not cause  intra-abdominal tumor bleeding [&lt;ulink linkID="780711" linkType="Reference"&gt;780711&lt;/ulink&gt;]. It was also reported that using cisplatin-resistant Cp70 ovarian cancer cells, a polycistronic cluster of microRNAs (miRs) were identified, which were significantly downregulated by 48 hr HDAC-42 treatment (but not by the identical treatment with vorinostat). The specific cluster, which includes miRs 302a, 302b, 302c, 302d and 367, were utilized  to identify several candidate genes that were potentially downregulated by the five mature miRs. It was found that miR302a possessed homology to several putative tumor supressor genes (including PDCD8, CFLAR and DOC1). In an additional study, it was found that oxidative damage was a strong contributing factor in HDAC-42 mediated growth inhibition, as antiproliferative activity was completely abrogated by the treatment with the antioxidant N-acetyl-cysteine (IC50 increased from 1.4 microM to 69 microM, a 49-fold decrease in drug potency). In   F344 rats, an iv bolus dose of OSU-HDAC-42 at 20 mg/kg resulted in a mean drug plasma concentration of 35.6 microM , which then decreased to 0.02 microM after  48 h. In a two-compartment model, the concentration-time profile of OSU-HDAC-42  gave initial and terminal half lives of 0.13 and 5.1 h, respectively. The mean AUC value was calculated as 52 microM/h and the total clearance (CL) was calculated to be 1.40 l/h/kg. Urinary excretion was found to be 5% of the dose and renal clearance as 0.017 l/h in 24 h. In a two-compartment model, following a 20 mg/kg iv bolus administration of R-HDAC-42, the plasma concentration-time profile gave  initial and terminal half lives of 0.3 and 4.1 h, respectively. The mean C0 was found to be 66.3 microM and the mean AUC value was 24.83 microM/h, which is smaller than that of OSU-HDAC-42. The mean CL, 2.61 l/h/kg, showed a corresponding increase for this isomer. The drug was absorbed quickly and the maximum plasma concentration (mean Cmax 7.1 microM) was reached within 1 h and remained relatively steady for a further 12 h following an oral dose of 50 mg/kg OSU-HDAC-42, and was still detectable up to 72 h. The mean AUC was 173 microM/h, which gave an oral bioavailability of around 100% [&lt;ulink linkID="777274" linkType="Reference"&gt;777274&lt;/ulink&gt;], [&lt;ulink linkID="780652" linkType="Reference"&gt;780652&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, preclinical data on OSU-HDAC-42 were presented at the  48th ASH meeting in Orlando, FL, demonstrating that the compound inhibited cell cycle progression in AML1/ETO-positive Kasumi-1 and PML/RARA-positive NB4 cells [&lt;ulink linkID="749230" linkType="Reference"&gt;749230&lt;/ulink&gt;]. Further data were presented from a study testing OSU-HDAC42 against CD19-positive cells obtained from patients with chronic myeloid leukemia (CLL). The LC50 of OSU-HDAC42 was 0.46 microM at 48 h of continuous incubation by MTT assay. The effects of OSU-HDAC42 were eliminated in CLL cells when the drug was removed after 4 or 6 h, but there was a gradual increase in effect over time, and by 16 h, approximately 60% of the cytotoxicity achieved with continuous incubation was retained. OSU-HDAC42 also sensitized CLL cells to TNF-related apoptosis inducing ligand (TRAIL) at 24 h in a dose-dependent manner [&lt;ulink linkID="750709" linkType="Reference"&gt;750709&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2006, preclinical data were presented on HDAC-42, VAD-18 and VAD-20 at the 97th AACR meeting in Washington DC. Following 72 h treatment, HDAC-42 exhibited potent antiproliferative activity against SKOV-3 and A2780 human ovarian carcinoma cells with IC50 values of  1.9 and   0.4 microM, respectively, and cisplatin-resistant CP70 (IC50 = 0.6 microM) cells. In normal ovarian surface epithelial cells, HDAC-42 had an IC50 value of 8.9 microM which was less toxic than &lt;ulink linkID="17625" linkType="Drug"&gt;SAHA&lt;/ulink&gt; (IC50 = 6.3 microM). Treatment with HDAC-42 (25 to 100 nM) resulted in a significant dose-dependent increase in hyperacetylated histones, H-3 and H-4 in human bladder cancer cell lines T24 (high-grade, invasive transitional cell carcinoma) and RT4 (low-grade, non-invasive papillary transitional cell carcinoma). After 24 h treatment, HDAC-42 (1 to 5 microM) showed a significant dose-dependent reduction in the expression of ErbB1 and ErbB2 in both cell lines and the compound significantly induced expression of ErbB3 in T24 cells. In PC-3 prostate cancer cells, a decrease in the surviving fraction was seen with increasing concentration of VAD-18 and VAD-20 and VAD-18 (IC50 = 0.5 microM) was shown to be more  cytotoxic than VAD-20 (IC50 = 7.5 microM).  HDAC-42 (Radiation Effect Reactor  (RER) = 9.8) was able to enhance the radiation effects in PC-3 cells much more effectively than VAD-18 (RER = 1.5) and VAD-20 (RER = 2.4). Up to 12 h post-treatment, a significant transient block in G2/M phase of the cell cycle was observed with either 2 Gy of radiation or drugs alone. Exposure to VAD-18 resulted in an additional delay following irradiation, while VAD-20 had a lesser effect. The levels of BclXL and Bcl2 reduced following combined treatment while levels of Bax increased. In CD1F2 mice, the AUC value was 43.7 microM/h and the total body clearance of HDAC-42 (20 mg/kg) was 1.47 L/h/kg. The oral bioavailability of HDAC-42 was shown to be 27.4% [&lt;ulink linkID="659685" linkType="Reference"&gt;659685&lt;/ulink&gt;], [&lt;ulink linkID="659688" linkType="Reference"&gt;659688&lt;/ulink&gt;], [&lt;ulink linkID="659685" linkType="Reference"&gt;659685&lt;/ulink&gt;], [&lt;ulink linkID="659457" linkType="Reference"&gt;659457&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, preclinical data on HDAC-42 were presented at the 96th AACR meeting in Anaheim, CA. In murine (MB49) and human (T24 and RT4) bladder cancer cell lines, HDAC-42 (0.1 to 10 microM) reduced cell viability both time- and dose-dependently (IC50 = 0.5 to 1.5 microM depending on cell line). HDAC-24 dose-dependently induced apoptosis at 24 h and at this time point produced a 50 to 100% decrease in S phase. G1 and G2 accumulation was observed in MB49 and RT4, respectively [&lt;ulink linkID="595624" linkType="Reference"&gt;595624&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By December 2017,  Arno entered into termination agreements with the licensor of  intellectual property relating to  &lt;ulink linkID="52558" linkType="Drug"&gt;AR-12&lt;/ulink&gt; and REC-2282,  following   which the parties agreed to terminate the related license agreements and release all claims against the other relating to the license agreements  [&lt;ulink linkID="1993745" linkType="Reference"&gt;1993745&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2008, Arno acquired worldwide exclusive rights from The Ohio State University (OSU) to develop and commercialize its small molecule oral formulation cancer therapies  [&lt;ulink linkID="871583" linkType="Reference"&gt;871583&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;para&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1096979">Recursion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3522">Neurofibromatosis type II</Indication><StatusDate>2019-01-04T00:00:00.000Z</StatusDate><Source id="2108363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3522">Neurofibromatosis type II</Indication><StatusDate>2017-11-30T00:00:00.000Z</StatusDate><Source id="2108363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2017-11-30T00:00:00.000Z</StatusDate><Source id="2108363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2802">Meningioma</Indication><StatusDate>2017-11-30T00:00:00.000Z</StatusDate><Source id="2108363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2017-11-30T00:00:00.000Z</StatusDate><Source id="2108363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1828">Multiple myeloma</Indication><StatusDate>2017-11-30T00:00:00.000Z</StatusDate><Source id="2108363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2464">Acoustic neuroma</Indication><StatusDate>2017-11-30T00:00:00.000Z</StatusDate><Source id="2108363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20649">Ohio State University</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3522">Neurofibromatosis type II</Indication><StatusDate>2019-01-04T00:00:00.000Z</StatusDate><Source id="2108363" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2010-06-17T00:00:00.000Z</StatusDate><Source id="1108806" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2013-08-21T00:00:00.000Z</StatusDate><Source id="1467844" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2802">Meningioma</Indication><StatusDate>2012-02-22T00:00:00.000Z</StatusDate><Source id="1265503" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3522">Neurofibromatosis type II</Indication><StatusDate>2012-03-19T00:00:00.000Z</StatusDate><Source id="1272842" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2464">Acoustic neuroma</Indication><StatusDate>2012-02-22T00:00:00.000Z</StatusDate><Source id="1265503" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2015-10-31T00:00:00.000Z</StatusDate><Source id="1760979" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20649">Ohio State University</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-01-28T00:00:00.000Z</StatusDate><Source id="871583" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20649">Ohio State University</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-04-17T00:00:00.000Z</StatusDate><Source id="595624" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037343">Arno Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-01-28T00:00:00.000Z</StatusDate><Source id="871583" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037343">Arno Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2802">Meningioma</Indication><AwardedIndication>Treatment of meningioma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-06-06T00:00:00.000Z</MileStoneDate><Source id="1298806" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037343">Arno Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2464">Acoustic neuroma</Indication><AwardedIndication>Treatment of schwannoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-06-06T00:00:00.000Z</MileStoneDate><Source id="1298806" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037343">Arno Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3522">Neurofibromatosis type II</Indication><AwardedIndication>Treatment of neurofibromatosis type 2</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-04-26T00:00:00.000Z</MileStoneDate><Source id="1289901" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037343">Arno Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2802">Meningioma</Indication><AwardedIndication>Treatment of meningioma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2012-04-12T00:00:00.000Z</MileStoneDate><Source id="1282471" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037343">Arno Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="2464">Acoustic neuroma</Indication><AwardedIndication>Treatment of schwannoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2012-04-12T00:00:00.000Z</MileStoneDate><Source id="1282471" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037343">Arno Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3522">Neurofibromatosis type II</Indication><AwardedIndication>Treatment of neurofibromatosis type 2</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2012-03-08T00:00:00.000Z</MileStoneDate><Source id="1272842" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037343">Arno Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="2802">Meningioma</Indication><AwardedIndication>Treatment of Schwannoma of the central nervous system</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-02-22T00:00:00.000Z</MileStoneDate><Source id="1265503" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1037343">Arno Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="2464">Acoustic neuroma</Indication><AwardedIndication>Treatment of Schwannoma of the central nervous system</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-01-13T00:00:00.000Z</MileStoneDate><Source id="1265503" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00922"><Name>Histone deacetylase</Name><SwissprotNumbers><Swissprot>O22446</Swissprot><Swissprot>P56521</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1037343">Arno Therapeutics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1096979">Recursion Pharmaceuticals LLC</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20649">Ohio State University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)[C@@H](c1ccccc1)C(=O)Nc2ccc(cc2)C(=O)NO</Smiles><Smiles>CC(C)C(c1ccccc1)C(=O)Nc2ccc(cc2)C(=O)NO</Smiles></StructureSmiles><Deals><Deal id="111440" title="Arno Therapeutics to develop OSU's cancer therapies worldwide      "/><Deal id="252576" title="Recursion to develop and commercialize OSIF's OSU-HDAC42 for NF2 worldwide"/></Deals><PatentFamilies><PatentFamily id="1041593" number="WO-2011143314" title="Compositions and methods for reducing proliferation and viability of lymphoblastoid cells"/><PatentFamily id="1659712" number="WO-2005055928" title="Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors"/><PatentFamily id="2802573" number="WO-2014164784" title="Hdac inhibitor polymorphic forms and methods of use"/><PatentFamily id="299846" number="WO-2011103563" title="Methods and compositions for inhibiting and preventing the growth of malignant mast cells"/><PatentFamily id="3560405" number="US-10022342" title="Methods and compositions for treating multiple myeloma"/><PatentFamily id="4434487" number="WO-2019055687" title="Methods and compositions for the treatment of cancer cachexia"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arno Therapeutics Inc" id="1037343"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohio State University" id="20649"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>